{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T03:57:30Z","timestamp":1775275050850,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40256-025-00725-0","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T17:59:03Z","timestamp":1741456743000},"page":"433-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Insights on DAPT Abbreviation and De-escalation from ULTIMATE-DAPT and Related Trials: Are we Heading Toward an Aspirin-Free Strategy?"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-2863","authenticated-orcid":false,"given":"Harshit","family":"Khare","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satyendra","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roopali","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"issue":"4","key":"725_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1161\/CIRCULATIONAHA.124.069012","volume":"150","author":"M Valgimigli","year":"2024","unstructured":"Valgimigli M, Landi A, Angiolillo DJ, Baber U, Bhatt DL, Bonaca MP, Capodanno D, Cohen DJ, Gibson CM, James S, Kimura T, Lopes RD, Mehta SR, Montalescot G, Sibbing D, Steg PG, Stone GW, Storey RF, Vranckx P, Windecker S, Mehran R. Demystifying the contemporary role of 12-month dual antiplatelet therapy after acute coronary syndrome. Circulation. 2024;150(4):317\u201335. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069012. (Epub 2024 Jul 22; PMID: 39038086).","journal-title":"Circulation"},{"key":"725_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.hjc.2023.01.005","volume":"71","author":"A Apostolos","year":"2023","unstructured":"Apostolos A, Chlorogiannis D, Vasilagkos G, Katsanos K, Toutouzas K, Aminian A, Alexopoulos D, Davlouros P, Tsigkas G. Safety and efficacy of shortened dual antiplatelet therapy after complex percutaneous coronary intervention: a systematic review and meta-analysis. Hellenic J Cardiol. 2023;71:33\u201341. https:\/\/doi.org\/10.1016\/j.hjc.2023.01.005. (Epub 2023 Feb 1; PMID: 36736730).","journal-title":"Hellenic J Cardiol"},{"issue":"1","key":"725_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/FJC.0000000000001503","volume":"83","author":"A Apostolos","year":"2024","unstructured":"Apostolos A, Travlos C, Tsioulos G, Chlorogiannis DD, Karanasos A, Papafaklis M, Alexopoulos D, Toutouzas K, Davlouros P, Tsigkas G. Duration of dual antiplatelet treatment after percutaneous coronary intervention in patients with diabetes: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2024;83(1):64\u201372. https:\/\/doi.org\/10.1097\/FJC.0000000000001503. (PMID: 37944149).","journal-title":"J Cardiovasc Pharmacol"},{"key":"725_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000001447","author":"A Apostolos","year":"2024","unstructured":"Apostolos A, Bozika M, Nastouli KM, Chlorogiannis DD, Dimitriadis K, Toutouzas K, Tsioufis K, Davlouros P, Tsigkas G. Duration of dual antiplatelet treatment after percutaneous coronary intervention in patients with chronic kidney disease: a systematic review and meta-analysis. Coron Artery Dis. 2024. https:\/\/doi.org\/10.1097\/MCA.0000000000001447. (Epub ahead of print; PMID: 39501903).","journal-title":"Coron Artery Dis"},{"key":"725_CR5","doi-asserted-by":"publisher","unstructured":"Ge Z, Kan J, Gao X, Raza A, Zhang JJ, Mohydin BS, Gao F, Shao Y, Wang Y, Zeng H, Li F, Khan HS, Mengal N, Cong H, Wang M, Chen L, Wei Y, Chen F, Stone GW, Chen SL, ULTIMATE-DAPT Investigators. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. 2024;403(10439):1866\u20131878. https:\/\/doi.org\/10.1016\/S0140-6736(24)00473-2 [Epub 2024 Apr 7. Erratum in: Lancet. 2024;403(10439):1854. https:\/\/doi.org\/10.1016\/S0140-6736(24)00929-2. PMID: 38599220].","DOI":"10.1016\/S0140-6736(24)00473-2"},{"issue":"8","key":"725_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","volume":"149","author":"SJ Hong","year":"2024","unstructured":"Hong SJ, Lee SJ, Suh Y, Yun KH, Kang TS, Shin S, Kwon SW, Lee JW, Cho DK, Park JK, Bae JW, Kang WC, Kim S, Lee YJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK, T-PASS (Ticagrelor Monotherapy in Patients Treated With New-Generation Drug-Eluting Stents for Acute Coronary Syndrome) Investigators. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation. 2024;149(8):562\u201373. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066943. (Epub 2023 Oct 25; PMID: 37878786).","journal-title":"Circulation"},{"issue":"23","key":"725_CR7","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2013.282183","volume":"310","author":"F Feres","year":"2013","unstructured":"Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusm\u00e3o M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL, OPTIMIZE Trial Investigators. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310(23):2510\u201322. https:\/\/doi.org\/10.1001\/jama.2013.282183. (PMID: 24177257).","journal-title":"JAMA"},{"issue":"3","key":"725_CR8","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","volume":"125","author":"HC Gwon","year":"2012","unstructured":"Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125(3):505\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.059022. (Epub 2011 Dec 16; PMID: 22179532).","journal-title":"Circulation"},{"issue":"3","key":"725_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s12928-015-0366-9","volume":"31","author":"M Natsuaki","year":"2016","unstructured":"Natsuaki M, Morimoto T, Yamamoto E, Shiomi H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Igarashi K, Tanabe K, Kozuma K, Kimura T. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial. Cardiovasc Interv Ther. 2016;31(3):196\u2013209. https:\/\/doi.org\/10.1007\/s12928-015-0366-9. (Epub 2015 Oct 30; PMID: 26518420; PMCID: PMC4923071).","journal-title":"Cardiovasc Interv Ther"},{"issue":"15","key":"725_CR10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y, RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60(15):1340\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2012.06.043. (Epub 2012 Sep 19; PMID: 22999717).","journal-title":"J Am Coll Cardiol"},{"issue":"10127","key":"725_CR11","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S0140-6736(18)30493-8","volume":"391","author":"JY Hahn","year":"2018","unstructured":"Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim SH, Jeong JO, Bae JH, Kim BO, Cho JH, Suh IW, Kim DI, Park HK, Park JS, Choi WG, Lee WS, Kim J, Choi KH, Park TK, Lee JM, Yang JH, Choi JH, Choi SH, Gwon HC, SMART-DATE Investigators. 6-Month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet. 2018;391(10127):1274\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(18)30493-8. (Epub 2018 Mar 12; PMID: 29544699).","journal-title":"Lancet"},{"key":"725_CR12","doi-asserted-by":"publisher","unstructured":"Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho BR, Oh SK, Yun KH, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC, SMART-CHOICE Investigators. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428\u201337. https:\/\/doi.org\/10.1001\/jama.2019.8146 [Erratum in: JAMA. 2019;322(13):1316. https:\/\/doi.org\/10.1001\/jama.2019.14331. PMID: 31237645; PMCID: PMC6593635].","DOI":"10.1001\/jama.2019.8146"},{"issue":"24","key":"725_CR13","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","volume":"321","author":"H Watanabe","year":"2019","unstructured":"Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414\u201327. https:\/\/doi.org\/10.1001\/jama.2019.8145. (PMID: 31237644; PMCID: PMC6593641).","journal-title":"JAMA"},{"issue":"37","key":"725_CR14","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1093\/eurheartj\/ehaa670","volume":"41","author":"U Baber","year":"2020","unstructured":"Baber U, Dangas G, Angiolillo DJ, Cohen DJ, Sharma SK, Nicolas J, Briguori C, Cha JY, Collier T, Dudek D, D\u017eavik V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta S, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han YL, Pocock S, Gibson CM, Mehran R. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020;41(37):3533\u201345. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa670. (PMID: 33085967).","journal-title":"Eur Heart J"},{"issue":"23","key":"725_CR15","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","volume":"323","author":"BK Kim","year":"2020","unstructured":"Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y, TICO Investigators. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407\u201316. https:\/\/doi.org\/10.1001\/jama.2020.7580. (PMID: 32543684; PMCID: PMC7298605).","journal-title":"JAMA"},{"issue":"10151","key":"725_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, M\u00f6llmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S, GLOBAL LEADERS Investigators. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)31858-0. (Epub 2018 Aug 27; PMID: 30166073).","journal-title":"Lancet"},{"issue":"13","key":"725_CR17","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jacc.2022.07.016","volume":"80","author":"PC Smits","year":"2022","unstructured":"Smits PC, Frigoli E, Vranckx P, Ozaki Y, Morice MC, Chevalier B, Onuma Y, Windecker S, Tonino PAL, Roffi M, Lesiak M, Mahfoud F, Bartunek J, Hildick-Smith D, Colombo A, Stankovic G, I\u00f1iguez A, Schultz C, Kornowski R, Ong PJL, Alasnag M, Rodriguez AE, Paradies V, Kala P, Kedev S, Al Mafragi A, Dewilde W, Heg D, Valgimigli M, MASTER DAPT Investigators. Abbreviated antiplatelet therapy after\u00a0coronary stenting in patients with\u00a0myocardial infarction at high\u00a0bleeding risk. J Am Coll Cardiol. 2022;80(13):1220\u201337. https:\/\/doi.org\/10.1016\/j.jacc.2022.07.016. (PMID: 36137672).","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"725_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","volume":"7","author":"H Watanabe","year":"2022","unstructured":"Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, Tatsushima S, Watanabe H, Ohya M, Tokuyama H, Tada T, Sakamoto H, Mori H, Suzuki H, Nishikura T, Wakabayashi K, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Morino Y, Kadota K, Furukawa Y, Nakagawa Y, Kimura T, STOPDAPT-2 ACS Investigators. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022;7(4):407\u201317. https:\/\/doi.org\/10.1001\/jamacardio.2021.5244. (PMID: 35234821; PMCID: PMC8892373).","journal-title":"JAMA Cardiol."},{"key":"725_CR19","doi-asserted-by":"publisher","unstructured":"Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, Ando K, Domei T, Suwa S, Ogita M, Isawa T, Takenaka H, Yamamoto T, Ishikawa T, Hisauchi I, Wakabayashi K, Onishi Y, Hibi K, Kawai K, Yoshida R, Suzuki H, Nakazawa G, Kusuyama T, Morishima I, Ono K, Kimura T. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation. 2024;149(8):585\u2013600. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066720 [Epub 2023 Nov 23. Erratum in: Circulation. 2024 May 14;149(20):e1189-e1190. https:\/\/doi.org\/10.1161\/CIR.0000000000001255. PMID: 37994553].","DOI":"10.1161\/CIRCULATIONAHA.123.066720"},{"issue":"5","key":"725_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ehjcvp\/pvad032","volume":"9","author":"M Valgimigli","year":"2023","unstructured":"Valgimigli M, Aboyans V, Angiolillo D, Atar D, Capodanno D, Halvorsen S, James S, J\u00fcni P, Kunadian V, Landi A, Leonardi S, Mehran R, Montalescot G, Navarese EP, Niebauer J, Oliva A, Piccolo R, Price S, Storey RF, V\u00f6ller H, Vranckx P, Windecker S, Fox KAA. Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. Eur Heart J Cardiovasc Pharmacother. 2023;9(5):462\u201396. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad032. (PMID: 37120728).","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"3","key":"725_CR21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/ehjcvp\/pvad016","volume":"9","author":"EP Navarese","year":"2023","unstructured":"Navarese EP, Landi A, Oliva A, Piccolo R, Aboyans V, Angiolillo D, Atar D, Capodanno D, Fox KAA, Halvorsen S, James S, J\u00fcni P, Kunadian V, Leonardi S, Mehran R, Montalescot G, Niebauer J, Price S, Storey RF, V\u00f6ller H, Vranckx P, Windecker S, Valgimigli M. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC). Eur Heart J Cardiovasc Pharmacother. 2023;9(3):271\u201390. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad016. (PMID: 36869784).","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"725_CR22","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1161\/CIR.0000000000001038","volume":"145","author":"JS Lawton","year":"2022","unstructured":"Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, Bittl JA, Cohen MG, DiMaio JM, Don CW, et al. 2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e18\u2013114. https:\/\/doi.org\/10.1161\/CIR.0000000000001038.","journal-title":"Circulation"},{"key":"725_CR23","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, Claeys MJ, Dan GA, Dweck MR, Galbraith M, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44:3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"issue":"8","key":"725_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/eurheartj\/ehad876","volume":"45","author":"P Capranzano","year":"2024","unstructured":"Capranzano P, Moliterno D, Capodanno D. Aspirin-free antiplatelet strategies after percutaneous coronary interventions. Eur Heart J. 2024;45(8):572\u201385. https:\/\/doi.org\/10.1093\/eurheartj\/ehad876. (PMID: 38240716).","journal-title":"Eur Heart J"},{"issue":"1","key":"725_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4244\/EIJ-D-22-00886.PMID:36734020;PMCID:PMC10173755","volume":"19","author":"NMR Van der Sangen","year":"2023","unstructured":"Van der Sangen NMR, Claessen BEPM, K\u00fc\u00e7\u00fck IT, den Hartog AW, Baan J, Beijk MAM, Delewi R, van de Hoef TP, Knaapen P, Lemkes JS, Marques KM, Nap A, Verouden NJW, Vis MM, de Winter RJ, Kikkert WJ, Appelman Y, Henriques JPS. Single antiplatelet therapy directly after percutaneous coronary intervention in non-ST-segment elevation acute coronary syndrome patients: the OPTICA study. EuroIntervention. 2023;19(1):63\u201372. https:\/\/doi.org\/10.4244\/EIJ-D-22-00886.PMID:36734020;PMCID:PMC10173755.","journal-title":"EuroIntervention"},{"issue":"15","key":"725_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35741.PMID:39170240;PMCID:PMC11336810","volume":"10","author":"S Yu","year":"2024","unstructured":"Yu S, Guo L, Guo H. Aspirin-free P2Y12 inhibitor monotherapy immediately after percutaneous coronary intervention: a systematic review. Heliyon. 2024;10(15): e35741. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35741.PMID:39170240;PMCID:PMC11336810.","journal-title":"Heliyon."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00725-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-025-00725-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-025-00725-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T07:08:26Z","timestamp":1751699306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-025-00725-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s40256-025-00725-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"17 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Harshit Khare, Satyendra Tewari, Roopali Khanna, and Aditya Kapoor have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Dr. Harshit Khare conceptualized and initially drafted the manuscript. Dr. Satyendra Tewari reviewed and analyzed the script. Dr. Roopali Khanna critically analyzed the script and provided insights for discussion. Dr. Aditya Kapoor is credited for supervision, visualization, and revision of the script.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' contributions"}},{"value":"Data sharing does not apply to this article as no datasets were generated for this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}